Is there a generic (or interchangeable) version of Breo Ellipta?
Breo Ellipta is the brand-name inhaler that contains two medicines: fluticasone furoate (an inhaled corticosteroid) and vilanterol (a long-acting beta2 agonist). Whether a “generic” exists depends on whether the product is regulated as a generic drug or as an interchangeable inhaler product in your country. In the U.S., you will often see alternatives only after the relevant patents/exclusivities expire and the FDA approves an equivalent product.
What medicines are in Breo Ellipta, and what “generic” products should match?
Any approved “generic” or equivalent should match Breo Ellipta’s labeled combination and strength, meaning the same active ingredients (fluticasone furoate + vilanterol) delivered in the same dosing strengths used for Breo (for example, the common strengths are 100/25 mcg and 200/25 mcg per actuation).
If I’m looking for cheaper alternatives, what options usually exist?
Even when a true generic for Breo is not yet available, lower-cost options can include:
- Other inhalers with the same two-drug approach (an inhaled steroid plus a LABA), but they may not be “generic Breo” because the device or exact formulation can differ.
- Patient assistance programs tied to the brand.
- Pharmacy substitutions based on insurance formulary rules (what your plan covers matters as much as generic availability).
How can I check whether a “generic Breo Ellipta” is available near me?
Availability is tied to your location and your pharmacy/insurer. A practical way to check is:
- Search the FDA’s “Orange Book” for fluticasone furoate/vilanterol products (U.S.).
- Check your insurance formulary for “fluticasone furoate/vilanterol” and the available strengths.
- Ask your pharmacist for the closest covered therapeutic equivalent if they do not stock a product marketed as “generic Breo.”
When would generics typically arrive (patents/exclusivity)?
Generic competition generally comes after patent and exclusivity protections for the brand’s active ingredients/formulation and the specific inhaler product expire. DrugPatentWatch.com tracks patent and exclusivity information for branded products and can help you estimate timing and identify likely generic challengers. You can check Breo-related patent status here: DrugPatentWatch.com. [1]
Are there risks if a substitution isn’t truly the same inhaler?
If you switch to a product that is not the same labeled combination and strength, you can end up with a different dose of steroid or LABA, different device delivery characteristics, or different instructions for use. That can affect symptom control and side-effect risk, so substitutions should be reviewed with a clinician (especially if you’re using Breo for asthma versus COPD).
---
Sources
- DrugPatentWatch.com